Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 1/20 | 0.60 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | FCER2 | P06734 | 2/20 | 0.55 |
| ▸ | MMP1 | P03956 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22649189 | 1.00 | CTSC (0.60) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL29372257 | 1.00 | CTSC (0.60) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL10049933 | 1.00 | CTSC (0.60) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL27755089 | 0.93 | ACE (0.60) | — | |
| Trifluoroacetic Acid SCHEMBL30164220 | 0.93 | PTPN1 (0.54) | CTSCFCER2MMP1 | |
| SCHEMBL29437738 | 0.93 | ACE (0.60) | — | |
| SCHEMBL30995919 | 0.92 | MME (0.55) | CTSC | |
| SCHEMBL22147415 | 0.92 | CTSC (0.52) | CTSCFCER2MMP1 | |
| SCHEMBL31289124 | 0.92 | MC4R (0.60) | CTSCFCER2 | |
| SCHEMBL31242458 | 0.91 | CTSC (0.57) | CTSCALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382918-A1 | RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS, AND USES THEREOF | Clarity Pharmaceuticals Ltd (AU) | 2023-11-30 | — | — | US | disclosed |
| US-11384088-B2 | Radiopharmaceuticals, radioimaging agents, and uses thereof | Clarity Pharmaceuticals Ltd (AU) | 2022-07-12 | — | — | US | disclosed |
| US-10975089-B2 | Radiopharmaceuticals, radioimaging agents, and uses thereof | Clarity Pharmaceuticals Ltd (AU) | 2021-04-13 | — | — | US | disclosed |
| WO-2021013085-A1 | PEPTIDE AMIDE SALT, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | 四川海思科制药有限公司 | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384088-B2 | Radiopharmaceuticals, radioimaging agents, and uses thereof | SLC30A5, SLC40A1, FOLH1 | CTSC 1106/4885ALPI 1790/4885PKM 2683/4885 |
| US-20230382918-A1 | RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS, AND USES THEREOF | SLC30A5, SLC40A1, FOLH1 | CTSC 1106/4885ALPI 1790/4885PKM 2683/4885 |
| US-10975089-B2 | Radiopharmaceuticals, radioimaging agents, and uses thereof | SLC30A5, SLC40A1, FOLH1 | CTSC 1106/4885ALPI 1790/4885PKM 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.